Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by Barclays

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by stock analysts at Barclays from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports.

A number of other equities analysts also recently commented on the stock. Bank of America reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Wednesday, July 23rd. Jefferies Financial Group decreased their target price on Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, July 24th. Leerink Partnrs lowered Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Piper Sandler lowered their target price on shares of Sarepta Therapeutics from $32.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, July 21st. Finally, Baird R W cut Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Six investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $49.12.

Sarepta Therapeutics Stock Up 14.2%

Shares of NASDAQ SRPT opened at $15.83 on Monday. The stock has a market capitalization of $1.56 billion, a PE ratio of -5.88 and a beta of 0.45. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The firm has a fifty day moving average of $25.16 and a 200-day moving average of $62.52. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $146.38.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.73 EPS. On average, analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its position in shares of Sarepta Therapeutics by 22.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company’s stock worth $773,000 after purchasing an additional 1,151 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Sarepta Therapeutics by 31.7% in the 4th quarter. Sei Investments Co. now owns 23,935 shares of the biotechnology company’s stock valued at $2,910,000 after acquiring an additional 5,764 shares in the last quarter. LPL Financial LLC increased its position in shares of Sarepta Therapeutics by 12.4% during the 4th quarter. LPL Financial LLC now owns 53,438 shares of the biotechnology company’s stock worth $6,497,000 after purchasing an additional 5,895 shares during the last quarter. Prudential Financial Inc. increased its holdings in Sarepta Therapeutics by 14.7% during the fourth quarter. Prudential Financial Inc. now owns 27,965 shares of the biotechnology company’s stock worth $3,400,000 after buying an additional 3,574 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Sarepta Therapeutics by 11.1% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,429 shares of the biotechnology company’s stock valued at $307,000 after purchasing an additional 243 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.